BerGenBio to Present at Pareto Securities’ 13th Annual Healthcare Conference
BERGEN, Norway, September 7, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at Pareto Securities’ 13th Annual Healthcare Conference in Stockholm, Sweden, on Wednesday, September 7, 2022, at 8:15am CEST. The presentation will be made available on the Company website in the presentations section on the day of the event: www.bergenbio.com/investors/presentations/ -End- Contacts